Cereno Scientific strengthens its clinical expertise, recruits top expert as Scientific Advisor
Cereno Scientific today announced that the company is strengthening its clinical expertise by recruiting Dr. Raymond L. Benza, Professor of Medicine and Director, Division of Cardiovascular Medicine, at the Ohio State University Wexner Medical Center in Columbus, USA, as Scientific Advisor to the company.
Earlier this March, Cereno Scientific was granted Orphan Drug Designation, by the U.S. Food and Drug Administration (FDA) for the company’s lead compound CS1 to treat the rare disease Pulmonary Arterial Hypertension (PAH), which is a form of high blood pressure in the lungs where the increased pressure is primarily caused by changes in the lung vessels. Dr. Benza’s primary clinical interests includes PAH and he is also a recognized investigator for the National Institutes of Health and the American Heart Association for his work in PAH.
“We are very pleased to welcome such an internationally renowned expert in cardiovascular and rare diseases as Scientific Advisor to Cereno Scientific. Dr. Raymond L. Benza has solid experience in PAH and we look forward to involve his expertise as we continue our development,” said Sten R. Sörensen, Chief Executive Officer of Cereno Scientific.
The purpose of engaging an expert Scientific Advisor is to support the company’s scientific development in the company’s focus areas of thrombosis and fibrosis-related rare cardiovascular diseases such as PAH.
More about Dr. Raymond L. Benza
Dr. Raymond L. Benza is Professor of Medicine and Director, Division of Cardiovascular Medicine at the Ohio State University Wexner Medical Center in Columbus, Ohio. Dr. Benza is an internationally renowned clinician and research scientist and his primary clinical interests are the evaluation and treatment of advanced congestive heart failure, cardiac transplantation, and PAH. He participates in major clinical studies of new therapies for the treatment of heart failure, mechanical support, and pulmonary hypertension. Dr. Benza was named Physician of the Year by the Pulmonary Hypertension Association in 2013 and serves on numerous national boards, committees, and councils related to his work in the field of advanced heart failure and pulmonary vascular disease. Dr. Benza is a funded investigator for the National Institutes of Health and the American Heart Association for his work in PAH focusing on risk stratification, pharmacogenomics and new device therapies for this disease state.
For further information, please contact:
Daniel Brodén – CFO
Tel: +46 768 66 77 87
E-mail: info@cerenoscientific.com
www.cerenoscientific.se
About Cereno Scientific AB
Cereno Scientific is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase II dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientific also evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation and high blood pressure in the pulmonary circulation system. The FDA has granted ODD for the indication Pulmonary Arterial Hypertension (PAH) to the company’s lead compund CS1. Cereno Scientific also has two preclinical HDAC inhibitors, CS014 and CS036. The company is located in AstraZeneca’s BioVenture Hub. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.